Ichnos Glenmark Innovation
Industry
- Biotechnology
- Large Molecule
- Antibodies
- Large Molecule
- Pharmaceuticals
Other Names/Subsidiaries
- Ichnos Sciences
Latest on Ichnos Glenmark Innovation
AbbVie is expanding its presence in the emerging field of trispecific antibodies for multiple myeloma with a second licensing deal, this time with IGI Therapeutics for ISB 2001, a CD38xBCMAxCD3-direct
Early data on Ichnos Glenmark Innovation’s (IGI) trispecific T-cell engager ISB 2001 in multiple myeloma presented at the American Society of Clinical Oncology (ASCO) meeting has signalled “deep and d
These are interesting times for Almirall and CEO Carlos Gallardo believes the Spanish firm holds “a unique position as the only company that focuses exclusively on medical dermatology and has capabili
Ichnos Glenmark Innovation (IGI) has a lot at stake as it readies to present first-time data from the Phase I study of its T cell-engaging trispecific antibody (ISB 2001) at the upcoming American Soci